🇺🇸United States·April 16, 2026·daily

US Merger & Acquisition SEC Filings — April 16, 2026

Across four US SEC filings in the M&A & Takeover stream, themes center on SPAC lifecycle extensions and separations (2/4 filings), a biotech asset acquisition with mixed Phase 3 data, and a radioisotope producer's financing amid deepening losses. Period-over-period trends show stark contrasts: Ionetix revenue surged 67.7% YoY to $6.0M for FY2025 but net loss widened 32.0% YoY to $39.7M, cash plummeted 94.6% to $0.3M, and assets fell 11.6% to $35.0M; MeiraGTx's acquisition highlights strong secondary endpoints (e.g., p=0.006 LLQ PRO mobility) despite primary endpoint miss. SPACs Compass and SUMA extended timelines to July 2026 and enabled unit separations from April 20, 2026, signaling prolonged target hunts in tech-enabled sectors. Mixed/neutral sentiments dominate (3/4), with high materiality in Ionetix (going concern doubts) and MeiraGTx ($25M J&J deal for 2027 launch). Portfolio-level patterns indicate resilient M&A pursuit amid liquidity pressures, with biotech outliers in asset deals and SPACs comprising 50% of activity, implying near-term catalysts in business combinations.

4 high priority4 total filings

🇺🇸United States·April 15, 2026·daily

US Merger & Acquisition SEC Filings — April 15, 2026

Across 9 SPAC filings in USA M&A & Takeover Activity, a dominant theme is deadline extensions and amendments in 6/9 cases (Pantages, Keen Vision, Ribbon, SIM, WinVest, indirectly Spring Valley), signaling sponsor commitment amid no completed deals, with total extension funding ~$335k via trust deposits and notes. Positive outliers include board expertise addition at Launchpad Cadenza and strategic tailings acquisition for Plum III's rare earth project (1.5M tons for 3M shares), contrasting mixed risks in Spring Valley's fusion merger. No YoY/QoQ operating trends available as pre-merger entities, but capital allocation trends show increasing sponsor loans/deposits (e.g., Ribbon $125k, WinVest $180k note with $60k drawn). Neutral-to-positive sentiment prevails (2 positive, 6 neutral, 1 mixed), with materiality highest (8/10) for active M&A updates. Portfolio-level pattern: SPAC sector under deadline pressure (original deadlines April-May 2026), driving activity spikes; implications include short-term upside on catalyst hits but redemption risks if unfulfilled. Forward-looking catalysts cluster late April, positioning for de-SPAC announcements.

9 high priority9 total filings

🇺🇸United States·April 14, 2026·daily

US Merger & Acquisition SEC Filings — April 14, 2026

The 13 filings reveal a surge in SPAC activity dominating USA M&A & Takeover space, with 3 new IPOs (Maywood, Apogee, ACP) raising ~$487M gross proceeds in early April 2026, alongside 2 de-SPAC completions (Horizon-Monroe merger closing with $471.7M pro forma assets; Haymaker-Suncrete despite pre-merger $31.5k net losses and going concern doubts). Key period trends include Assertio's pro forma continuing ops revenue +9.7% YoY to $68.2M (2025 vs 2024) but net loss widening 14.2% YoY to $31.3M, offset by $35M asset sale boosting cash to $45.2M and equity to $109.5M; discontinued ops showed $50.5M rev/$11.4M NI pre-sale. Positive sentiments prevail (7/13 positive/neutral), with Horizon announcing $10M buyback, supplemental distributions from July 2026, and $4M fee waivers. Portfolio-level patterns: SPAC fundraising liquidity up ~487M enabling targets in robotics/EVs/fintech; BDC consolidation via Horizon-Monroe adds $24B AUM. Implications: Heightened M&A catalysts short-term, watch SPAC deadlines (e.g., Suncrete July 28) and post-merger integrations for alpha.

13 high priority13 total filings

🇺🇸United States·April 13, 2026·daily

US Merger & Acquisition SEC Filings — April 13, 2026

A remarkable surge in USA M&A and takeover activity on April 13, 2026, with 11 filings dominated by SPAC business combinations and asset acquisitions in high-growth AI sectors including fintech lending, healthcare analytics, defense detection, and video intelligence. Five positive-sentiment deals (IVCA-Blue Finance $220M, Sizzle-Trasteel $800M, CCTC AI IP, PHGE-DFSL defense, VWAV-xClibre $60M IP) highlight bullish M&A momentum, with no reported YoY/QoQ financial declines but forward-looking earnouts and milestones signaling growth potential. Neutral filings reflect SPAC lifecycle pressures like 3 extensions (Future Vision II $191K note, Inception $12K deposit) and 1 adjournment (Ribbon to Sep 2026), indicating sponsor commitment amid deadline risks but no insider selling or capital cuts. High materiality averages 7/10, with portfolio-level pattern of AI-themed takeovers (4/11 filings) vs routine SPAC housekeeping (4/11). Market implications: Elevated pre-close volatility for SPACs, alpha in AI M&A targets; no sector-wide margin compression or ratio deteriorations noted. Catalyst calendar dense with shareholder votes, F-4 filings, and H2 2026 POCs.

11 high priority11 total filings

🇺🇸United States·April 10, 2026·daily

US Merger & Acquisition SEC Filings — April 10, 2026

The 14 filings reveal a surge in SPAC activity with 5 new IPOs/extensions/appointments signaling renewed M&A appetite in blank-check vehicles targeting tech, private credit, and advanced materials, amid 3 director resignations and 1 delisting highlighting sector churn. Actual M&A progressed with BiomX's acquisition of Zorronet (AI defense tech) from Nukkleus, FG Merger's Boxabl deal extension to July 31, 2026, and Compass Digital's merger with Key Mining, while Ashford Hospitality's $40.5M hotel sale improved pro forma operating income 18.5% YoY to $137.9M and narrowed net loss 10.7% to $(191.8M). Jet.AI's 1-for-200 reverse split reduced shares 99.5% to maintain Nasdaq compliance, freeing shares for potential future deals. No broad insider trading activity noted, but board additions in Iron Horse, T-REX convey management conviction; sentiments skew positive/neutral (10/14) with SPAC governance tweaks dominating. Portfolio-level trends show asset sales/debt reductions enhancing balance sheets (e.g., Ashford net debt -1.6% pro forma), positioning for M&A catalysts. Distressed signals in Quetta (MVLS failure post-180 days) contrast bullish IPO momentum ($350M+ raised), implying selective opportunities in dealflow-ready SPACs vs. fading ones.

14 high priority14 total filings

🇺🇸United States·April 09, 2026·daily

US Merger & Acquisition SEC Filings — April 09, 2026

The 11 filings reveal surging SPAC-driven M&A activity, with 4 major business combination announcements (Mountain Lake $3.25B quantum, Constellation $571M lithium, Fifth Era strategic metals, Willow Lane proxy risks) targeting high-tech and critical minerals, signaling strong investor appetite for strategic assets amid 2026 deal rebound. Completed transactions dominate positives: Sealed Air's $10.3B take-private at $42.15/share delisting and Ovintiv's $3.0B Anadarko divestiture funding debt target achievement and returns. Neutral unit separations (Paloma, GalaxyEdge) enhance liquidity, while extensions (byNordic 9th to May 12), Nasdaq issues (DT Cloud Star <400 holders), and control weaknesses (Boost Run unremediated into 2026) highlight SPAC persistence risks. No uniform PoP financial trends across filings, but aggregate deal valuations exceed $17B, with positive sentiment in 6/11 (55%) vs negative/mixed in 3/11. Portfolio implications: Bullish de-SPAC catalysts in quantum/lithium/metals; caution on SPAC delays/compliance; energy firms optimizing balance sheets for returns.

11 high priority11 total filings

🇺🇸United States·April 08, 2026·daily

US Merger & Acquisition SEC Filings — April 08, 2026

The 7 filings underscore a vibrant SPAC and M&A landscape on April 8, 2026, dominated by routine post-IPO unit separation announcements in 4 blank check companies (Abony, Averin, Metals II, and contextually similar), signaling increased liquidity and readiness for business combinations in defense tech, health/tech, and metals sectors. Key outliers include Air Lease Corp's takeover completion by Sumisho (rename and capital restructure), DMAA's positive $1B non-binding LOI with Power Analytics Global Corp for de-SPAC (min $25-50M cash, potential PIPE), and Eureka Acquisition Corp's dual negative developments: a $150k working capital promissory note and delisting notice effective April 6. Sentiment is neutral across 5/7 filings, positive for DMAA (high materiality 9/10), and negative for Eureka delisting (9/10 materiality), with no explicit period-over-period financial trends but clear forward-looking catalysts like unit separations April 10-14 and LOI progression. No insider trading or capital allocation shifts beyond Air Lease's stock reclassification and preferred series designations noted; transaction details highlight undervalued SPAC targets ($750M-$1.5B for Abony) vs DMAA's $1B valuation. Portfolio-level pattern: SPAC maturation post-IPO accelerates M&A potential, but delisting risks underscore selection discipline. Implications: Bullish for de-SPAC hunters in targeted sectors, bearish caution on distressed SPACs like Eureka.

7 high priority7 total filings

🇺🇸United States·April 07, 2026·daily

US Merger & Acquisition SEC Filings — April 07, 2026

The April 7, 2026, USA M&A & Takeover Activity stream reveals a robust wave of transaction completions and progressions, with 8 out of 15 filings announcing deal closures including high-profile takeovers (Hologic by Blackstone/TPG at up to $79/share), acquisitions (Runway of SWK boosting assets to $1.2B pro forma), and divestitures (CVD Equipment's SDC sale for $16.9M cash). SPAC activity dominates the first 7 new filings, featuring 5 deadline extensions or combination advancements (Aquaron, Athena, Real Asset-IQM, Alchemy-Cartiga, Haymaker non-redemption), signaling sustained merger momentum amid redemption pressures. Period-over-period pro forma trends show mixed results: revenue declines in Ginkgo (-22% to $132.7M for 2025 post-Biosecurity spin) and TCW Direct Lending (-70% NII to $30M), contrasted by Runway's healthcare exposure doubling to 32% and stable NAVs in TCW exchanges. Positive sentiments prevail (9/15 filings), with capital deployed into strategic assets (Supernus psychiatry pipeline, Northwest CDMO), enhancing focus but highlighting profitability challenges in biotech. Portfolio-level implications favor monitoring SPAC catalysts for de-SPAC pops and post-merger integration risks in finance/healthcare sectors.

15 high priority15 total filings

🇺🇸United States·April 06, 2026·daily

US Merger & Acquisition SEC Filings — April 06, 2026

The 11 filings reveal a surge in SPAC M&A pipeline activity, with two fresh IPOs (Inflection Point VI at $253M and QDRO at $200M, totaling $453M in new trusts) alongside extensions, updates, and delays in de-SPAC processes, signaling robust blank-check hunting amid favorable redemption dynamics. Completed takeovers dominate high-materiality events: Howmet's $1.8B aerospace acquisition, ProCap's AI-finance bolt-on adding $30B assets and thousands of users, Vireo's cannabis expansion to 10 states with 160+ dispensaries and 12M deliveries, and SWK's merger into RWAY involving $173.5M cash + 6.33M shares issued. Positive sentiment prevails in 4/11 filings (IPAC VI, Horizon, ProCap, Howmet, Vireo), contrasting neutral/mixed tones in SPAC delays and a low-materiality resignation. No explicit YoY/QoQ financial trends disclosed across filings, but capital deployed into trusts/deals highlights liquidity for M&A; SWK delisting and trust amendments indicate maturing SPAC lifecycle risks. Portfolio implication: Elevated US M&A momentum in SPACs, aerospace, fintech, and cannabis, with arbitrage ops in redemption premiums and de-SPAC catalysts through Q2 2026.

11 high priority11 total filings

🇺🇸United States·April 03, 2026·daily

US Merger & Acquisition SEC Filings — April 03, 2026

The six SPAC filings reveal a bifurcated US M&A landscape with fresh momentum in de-SPAC transactions and IPOs contrasted by compliance distress and financing strains; Crown Reserve's Carvix merger and Future Money's $115.6M IPO (including $112M public + $3.04M private placement) signal robust deal activity, while JENA's NYSE non-compliance and DMII's sponsor transition highlight sector headwinds. No explicit YoY/QoQ financial trends or operational metrics reported across filings, but forward-looking timelines cluster catalysts in 45 days (JENA plan), 4-6 months (DMII deal execution), and 3-year earnouts (Crown). Insider activity absent; capital allocation focused on trust deposits (Future Money) and debt amendments (Inflection Point note up 14% QoQ from $700k to $800k). High materiality developments (avg 7.5/10) underscore SPAC revival potential amid regulatory risks, with positive sentiment in 2/6 filings driving takeover opportunities. Portfolio-level pattern: 4/6 newly published filings show financing/de-SPAC urgency, implying accelerated M&A timelines versus stagnant peers.

6 high priority6 total filings

🇺🇸United States·April 02, 2026·daily

US Merger & Acquisition SEC Filings — April 02, 2026

A surge in US M&A and takeover activity is evident across 20 filings on April 2, 2026, with 12 completions or announcements including strategic acquisitions in energy, pharma, retail, investment management, avionics, and buses, alongside 2 divestitures of non-core assets netting $24.8M and $70M cash respectively. SPACs dominate with 7 filings focused on unit separations, extensions, merger approvals, and amendments, signaling sustained deal hunting amid low redemptions (e.g., 1,153 shares in Tech & Tele). Positive sentiment prevails in 10/20 filings (50%), driven by accretive deals adding capacity (395MW Kodiak), AUM ($1.63B Bimini), revenue streams (Abundia Q2), and portfolio diversification, while mixed/neutral tones in divestitures and administrative updates. Period-over-period data limited but notable: Ashford pro forma revenue -1.6% YoY to $1.087B but net loss improved 16.5% to $157M excluding underperformer. No insider trading reported; forward-looking highlights include immediate accretion (Kodiak), Q2 revenue (Abundia), 2027 earnouts (Crown), and integration catalysts. Portfolio-level: M&A valuations range $200M-$1B EV, emphasizing bolt-ons for growth; implications point to sector consolidation in energy/industrials, SPAC revival.

20 high priority20 total filings

🇺🇸United States·April 01, 2026·daily

US Merger & Acquisition SEC Filings — April 01, 2026

A surge in US M&A and takeover activity dominates the 30 filings, with 12 bank/regional financial mergers completing on April 1, 2026 (e.g., CWBC/UBFO at $185.5M, SPFI/BOH adding $744M assets, FirstSun/First Foundation creating $20.4B asset entity), signaling aggressive consolidation in regional banking amid $5B-$34B combined asset footprints. SPAC ecosystem thrives with 6 IPO pricings/LOIs (e.g., Future Money $100M, QDRO $200M) and preparatory restructurings, while divestitures (8 cases) boost pro forma cash (e.g., Duke $2.48B proceeds, CHS $459M gain) but compress revenues (avg -15% YoY pro forma across 7 with data). Spin-offs like Versigent (Aptiv carve-out, $8.8B rev +3% YoY, EBITDA to expand 200bps over 3yrs) and mixed JV/deals (Lands' End $300M IP swap) highlight portfolio optimization. Portfolio-level trends show pro forma net income gains from one-time sale gains (avg +100% in 5 cases) offsetting op rev declines (-1.8% to -55%), with positive sentiment in 70% of filings. Implications: Regional banks gain scale for efficiency; watch summer 2026 systems conversions as catalysts; SPACs signal dry powder for de-SPAC waves.

30 high priority30 total filings

🇺🇸United States·March 31, 2026·daily

US Merger & Acquisition SEC Filings — March 31, 2026

Across 10 US SEC filings focused on M&A and takeover activity in the period ending March 31, 2026, a surge in deal completions dominates, including 4 de-SPAC mergers/IPOs/amendments (Trailblazer/Cyabra, Soulpower, Spartacus, Inflection Point, Live Oak), 3 acquisitions (SCYNEXIS, Spire, Oramed/Lifeward), 2 divestitures (BrightSpring, Oramed), and 1 share authorization (Mobivity), signaling robust M&A momentum in biotech, utilities, health services, and SPACs. No explicit period-over-period financial declines reported; instead, themes of portfolio optimization via divestitures and bolt-on acquisitions highlight strategic refocusing without margin compression or YoY revenue drops noted. SPAC activity is particularly hot with 5 filings, pro forma valuations up to $8.5B (Soulpower), and trading commencements imminent. Positive sentiment prevails in 7/10 filings (avg materiality 8.5/10), with forward-looking catalysts like Phase 2 trials (SCYNEXIS Q4 2026) and EPS growth targets (Spire 5-7%). Mixed/neutral tones in Soulpower (closing delay), Live Oak, and Mobivity flag execution risks. Implications: Investors should prioritize post-deal liquidity events and pipeline readouts for alpha, as capital allocation favors growth via M&A over buybacks/dividends.

10 high priority10 total filings

🇺🇸United States·March 30, 2026·daily

US Merger & Acquisition SEC Filings — March 30, 2026

The March 30, 2026, filings reveal heightened USA M&A and takeover activity, with 4 major acquisitions/divestitures (Leidos $2.4B, Addentax control stake, Bitmine blockchain assets, Aimco $455M property sale) signaling strategic expansion in energy infrastructure, fashion, crypto staking, and REIT portfolio optimization. SPACs dominate the rest, with extensions (Constellation to April 29), redemptions (ASPAC shares down 71% YoY post-Oct), resignations (UY Scuti CFO), and voting (Relativity), reflecting ongoing deal pursuits amid deadline pressures. Positive sentiment prevails in 4/8 filings (50%), mixed in Aimco due to pro forma revenue decline 33% to $92.6M for 2025 despite liquidity boost (cash +$547.5M, debt -to $457.3M). No insider trading or dividend changes noted across filings, but transaction terms highlight deferred payments/earnouts (Bitmine $14M deferred + $11.8M earnout). Portfolio trend: Acquirers gaining scale (Leidos doubling energy presence), SPACs managing liquidity for catalysts; watch SPAC merger votes for takeover upside.

8 high priority8 total filings

🇺🇸United States·March 27, 2026·daily

US Merger & Acquisition SEC Filings — March 27, 2026

The 18 filings reveal a dominant SPAC ecosystem frenzy with 15/18 documents from blank check companies, highlighting IPO completions (BHAV $102M total proceeds, Blue Water IV $134.25M, TRG partial over-allotment to $206.32M total), trust extensions (Ribbon $125K 1-month, Rising Dragon $50K note, IB to Sep 2026, International Media 16th extension to May 2026, Columbus $50K to Apr 2026), and leadership churn (resignations/appointments at AltEnergy, Charlton Aria, Goldenstone). Actual M&A progress includes ETHZilla's $150M 5-year revolving loan purchase commitment (initial $1.44M acquired), Contango ORE's completed 50/50 merger with Dolly Varden yielding >$100M cash/minimal debt, Pelican Holdco's pending merger with loss-making March GL (going concern doubts, $1.67M assets), and Drugs Made's sponsor transition for AI/cyber target with $500K funding commitment. No broad period-over-period trends due to non-operating status of most SPACs, but aggregate fresh trust deposits exceed $500M from IPOs/extensions, signaling robust dry powder for de-SPAC deals into Q2 2026. Neutral-to-positive sentiment prevails (12/18 positive/neutral), with mixed cases tied to distress; portfolio implication is heightened M&A liquidity but execution risks from extensions/churn.

18 high priority18 total filings

🇺🇸United States·March 26, 2026·daily

US Merger & Acquisition SEC Filings — March 26, 2026

The 8 filings highlight intense SPAC maneuvering amid M&A completions in niche sectors like crypto blockchain and industrial/pharma mergers, with 5/8 filings from blank-check companies (Soulpower, Launch One, Haymaker, IB, Metal Sky) showing extension efforts, financings, and governance changes versus 3 actual deal closures (Atlantic, Crypto Co, Enzon). Key trends include heavy SPAC redemptions (e.g., IB's $7.9M outflow leaving $8.2M trust) and sponsor support via notes/preferred stock, signaling prolonged hunts for targets; no broad YoY/QoQ financial trends reported but capital raises average ~$1.25M principal across notes/preferred for working capital/BC. Positive catalysts emerge from Crypto Co's milestone-based IP acquisition with 2026 blockchain launch and Enzon's all-stock merger (45/55 ownership split), boosting interoperability and operational scale. Mixed sentiment prevails (3 neutral, 2 positive, 1 mixed) with materiality skewed high (5/8 at 7-9/10) on deal-related filings, implying near-term volatility in SPACs but alpha in completed M&A. Portfolio-level pattern: SPACs face redemption pressures (1/5 with quantified $7.9M drain) versus accretive deals with no upfront dilution.

8 high priority8 total filings

🇺🇸United States·March 25, 2026·daily

US Merger & Acquisition SEC Filings — March 25, 2026

A surge in US M&A and takeover activity dominates the week's filings, with 7 events spanning SPAC milestones (IPOs, amendments, unit separations), strategic acquisitions in food (FDP $285M Del Monte assets), cannabis (Vireo <4x EBITDA dispensaries/manufacturing), medtech (Lifeward amendment), and a mining divestiture (Hecla $160M cash + 65.8M shares + $321M contingent). Positive sentiment prevails in 5/7 filings (71%), with high materiality (avg 8/10) signaling portfolio-level M&A acceleration amid SPAC resurgence; no explicit YoY/QoQ revenue trends but deal-driven growth implied via platform expansions and low-multiple buys. Key developments include Hecla's deleveraging ($263M note redemption April 9) and FDP's brand reunion after 40 years, enhancing efficiency but flagging integration risks. Cross-company patterns show capital recycling (divest-to-acquire/reinvest), SPAC dry powder influx ($125M Blue Water IPO), and forward-looking catalysts like earnouts (Athena 25.5M shares) and dispensary scaling (Vireo to 75+). Implications: Bullish for M&A targets and post-deal synergies, watch SPAC closings for de-SPAC pops; sector tailwinds in cannabis/food/mining divestitures boost shareholder value via accretive deals.

7 high priority7 total filings

🇺🇸United States·March 24, 2026·daily

US Merger & Acquisition SEC Filings — March 24, 2026

The 9 filings reveal a bifurcated US M&A landscape dominated by SPAC activity (6/9 filings), with progress via PIPE financings, non-redemption agreements, and administrative setups contrasting sharply against Oak Woods' imminent delisting for failing to complete a business combination within 36 months. Completed deals in operating companies show mixed pro forma impacts: LSI Industries' $325M acquisition boosts combined TTM revenue to $864M (+46% vs LSI standalone $593M) and EBITDA margin to 11% (from 9.7%), while Cardlytics' $25.4M divestiture narrows 2024 net losses 79% to $(40.4M) despite 8-9% revenue declines YoY. Playboy's JV sale secures $122M in contracted cash through 2033, enabling debt paydown and immediate earnings accretion. Period-over-period trends highlight profitability improvements post-transaction (e.g., Cardlytics net loss per share to $(1.72) in 2025) amid revenue softness, signaling portfolio-level deleveraging and strategic refocus. No insider trading or dividend/buyback changes noted across filings, but capital allocation leans toward debt reduction (Playboy) and acquisition funding via debt/equity (LSI). SPAC advancements build toward catalysts like S-4 filings and closings, while distress in one underscores sector risks.

9 high priority9 total filings

🇺🇸United States·March 24, 2026·daily

US Merger & Acquisition SEC Filings — March 24, 2026

The 9 filings reveal robust M&A and takeover activity dominated by SPACs (6/9 filings) facing mixed fortunes, including PIPE financings, non-redemption support, administrative deals, but also delisting risks, alongside operating company divestitures and acquisitions showing pro forma financial improvements. Key period-over-period trends include revenue declines in divested units (Cardlytics: 2025 revenue down 9% pro forma to $212.3M) but narrower net losses (79% improvement in 2024 to $(40.4M)), EBITDA margin expansion via accretive deals (LSI: combined 11% from 9.7%), and secured future cash flows (Playboy: $122M contracted through 2033). Critical developments like LSI's $325M acquisition and Playboy's $15M JV sale signal strategic portfolio optimization, while SPAC challenges (Oak Woods delisting March 25, 2026) highlight deadline pressures post-36 months. Portfolio-level patterns show 3/9 with positive pro forma metrics (narrower losses, higher EBITDA), contrasting SPAC neutral/negative sentiment; sector themes point to industrials/licensing M&A strength amid SPAC fatigue. Implications favor monitoring post-deal integrations and SPAC closings for near-term catalysts, with asset-light shifts boosting returns.

9 high priority9 total filings

🇺🇸United States·March 23, 2026·daily

US Merger & Acquisition SEC Filings — March 23, 2026

The 10 filings reveal heightened US M&A and takeover activity dominated by SPACs (7/10 filings), with extensions, approvals, and high redemptions signaling persistent deal momentum amid liquidity pressures; actual sector M&A includes mining consolidation (Coeur-New Gold boosting 2026 gold production guidance 80% YoY from 419k oz to 680-815k oz), reinsurance divestiture (FG Nexus), crowdfunding expansion (StartEngine-Vinovest adding $140-150M AUM), and governance tweaks post-acquisition (Exact Sciences). Period-over-period trends show SPAC trust deposits for extensions (YHN $150k) contrasting low balances (TETE $142k signaling redemptions), while Coeur's reserves integration extends mine life to 2032-2035 with strong FCF projections. Capital allocation shines in Coeur's $750M buyback and inaugural $0.02/share dividend vs prior $400M facility upgrade to $1B revolver. Overarching themes: SPAC resilience via extensions/name changes (Goldenstone to Chi Special) but delisting risks (Bayview); positive sentiment in 6/10 filings drives alpha in mining/alts, mixed in SPACs due to redemptions (Crane 19.4M shares/$201M). Portfolio implication: Favor completed M&A with guidance upside over pre-merger SPACs; monitor March 26-31 catalysts for volatility.

10 high priority10 total filings